MELBOURNE, AUSTRALIA–(Marketwired – Jul 25, 2016) – Opthea Limited (ASX: OPT) (OTCQX: CKDXY), a developer of novel biologic therapies for the treatment of eye diseases, will host a conference call at 10:30am Australian Eastern Daylight Time on Tuesday, July 26 (8:30pm US EDT on Monday, July 25). The Company will discuss results from its Phase 1 dose escalation study of drug candidate OPT-302 in patients with wet age-related macular degeneration (wet AMD). 

Source: http://www.marketwired.com/mw/release.do?id=2144819&sourceType=3

This entry was posted on Monday, July 25th, 2016 at 1:15 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.